Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00954174 (A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma), which is not on this map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Who cites it
59 citing papers in PubMed, 91 citations in OpenAlex.
- A High-Fidelity and Ancestrally Inclusive Patient-Derived Organoid Platform Resolves Cancer Cell Plasticity in Uterine Carcinosarcoma.bioRxiv : the preprint server for biology · 2026Article
- Prognostic Implications of Combined p53 and Mismatch-Repair Immunophenotypes in Uterine Carcinosarcoma.Medicina (Kaunas, Lithuania) · 2026Article
- Ovarian Carcinosarcoma With Heterologous Chondrosarcomatous Differentiation: A Case Report and Review of Literature.Cureus · 2026Article
- A rare case of uterine carcinosarcoma in a 21-year-old woman with hereditary breast and ovarian cancer syndrome: A case report.Oncology letters · 2026Article
- Article
- PACAP Alleviates Paclitaxel-Induced Peripheral Neuropathy by Targeting Oxidative Stress and Mitochondrial Damage via the PGC-1α Pathway.CNS neuroscience & therapeutics · 2026Article
- Clinical Characteristics and Treatment Outcomes in Ovarian Carcinosarcoma: A Retrospective Cohort Study of 90 Cases.International journal of women's health · 2026Article
- Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.Gynecologic oncology · 2025Article
- Article
- Article
- Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.Gynecologic oncology reports · 2025Article
- Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis.Journal of gynecologic oncology · 2025Article
- Carcinosarcoma of the Endometrium-Pathology, Molecular Landscape and Novel Therapeutic Approaches.Medicina (Kaunas, Lithuania) · 2025Review
- Unconventional success: Achieving long-term remission with pembrolizumab in recurrent high-grade endometrial carcinosarcoma.Gynecologic oncology reports · 2025Article
- Article
- Surgical staging identifies occult metastases in over 50% of uterine-confined carcinosarcoma.Gynecologic oncology reports · 2025Article
- Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2025Review
- Article
- A rare case report of uterine carcinosarcoma with bilateral ovarian Brenner tumors.Frontiers in oncology · 2025Article
- GTSF1 promotes stemness in uterine carcinosarcoma through CCL1-mediated M1 macrophage aggregation.American journal of cancer research · 2025Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 13 institutions in 1 country.
Funding
Abstract
purposeThis phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS). PATIENTS AND
methodsAdults with chemotherapy-naïve UCS or ovarian carcinosarcoma (OCS) were randomly assigned to PC or PI with 3-week cycles for 6-10 cycles. With 264 events in patients with UCS, the power for an overall survival (OS) hybrid noninferiority design was 80% for a null hazard ratio (HR) of 1.2 against a 13% greater death rate on PI with a type I error of 5% for a one-tailed test.
resultsThe study enrolled 536 patients with UCS and 101 patients with OCS, with 449 and 90 eligible, respectively. Primary analysis was on patients with UCS, distributed as follows: 40% stage I, 6% stage II, 31% stage III, 15% stage IV, and 8% recurrent. Among eligible patients with UCS, PC was assigned to 228 and PI to 221. PC was not inferior to PI. The median OS was 37 versus 29 months (HR = 0.87; 90% CI, 0.70 to 1.075;
conclusionPC was not inferior to the active regimen PI and should be standard treatment for UCS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.